👉Differentiated thyroid cancer is a frequent diagnosis and includes malignancies with diverse clinical behavior. Although overall prognosis is excellent, treatment carries substantial morbidity risks. Stratification of risk, based on pathology, tumor biology, ongoing biochemical and imaging assessments, and patient comorbidities, now forms the essential basis of DTC management with an imperative to provide care that is individualized and disease appropriate.











👉Rodrigo Arrangoiz MS, MD, FACS a head and neck surgeon / endocrine surgeon / breast surgeon / surgical oncologist and is a member of Sociedad Quirúrgica S.C at the America British Cowdray Medical Center in Mexico City
👉He just publishes a manuscript summarizing the management of thyroid cancer:
https://www.scirp.org/pdf/IJOHNS_2019111315113453.pdf

👉Training:
• General surgery:
• Michigan State University:
• 2004 al 2010
• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• Fox Chase Cancer Center (Filadelfia):
• 2010 al 2012
• Masters in Science (Clinical research for health professionals):
• Drexel University (Filadelfia):
• 2010 al 2012
• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• IFHNOS / Memorial Sloan Kettering Cancer Center:
• 2014 al 2016





